An observational study in Gastric Cancer, Pancreatic Fistula and Complication, sponsored by Shanghai Zhongshan Hospital. Status unknown at 21 sites in China. Per ClinicalTrials.gov, last updated 2018-01-05.
Sponsored by Shanghai Zhongshan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital — 12 open to participants now, 13 under way, none of them phase 3. Stomach Neoplasms · Shanghai Zhongshan Hospital.
Among the 30 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital, this one is the 2nd largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2017, is one of 12 observational ones, and was the 11th registered.
3,401 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →12 of the 30 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–79
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18–74
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 2
First in 2008; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,100 is above the median of 276 across 791 observational studies indexed under Stomach Neoplasms.
Median enrollment 57 across the 18 interventional studies, 462 across the 12 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Zhongshan Hospital is the lead sponsor of 652 studies on the registry; 291 are open to participants now.
2 of the studies in Stomach Neoplasms by Shanghai Zhongshan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05311189Shanghai Zhongshan HospitalStudy of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | 2026-12-31 |
| NCT07333573Shanghai Zhongshan HospitalA Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to investigate the incidence of pancreatic fistula after radical gastrectomy in gastric cancer patients.
Pancreatic fistula, which can lead to fatal end, is one of the most serious complications after radical gastrectomy. It is usually treated as a key factor to evaluate the quality of gastrectomy. The incidence of pancreatic fistula is far different between different areas, knowing the prevalence of pancreatic fistula and risk factors can help us to prevent pancreatic fistula and improve the short time outcome of gastric cancer surgery treatment. So, we designed this perspective, multi-center study to investigate the incidence of pancreatic fistula and its outcome in China.
stomach adenocarcinoma patients who recieved radical gastrectomy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
gastric cancer patients receiving radical gastrectomy
Diagnostic Test: Amylase Test
body fluid amylase will be tested after radical gastrectomy in scheduled interval
Incidence of Pancreatic Fistula
the incidence of pancreatic fistula after radical gastrectomy in gastric cancer patients
Time frame: in 30 days following gastrectomy
The Classification of Pancreatic Fistula
the percentage of different grades of pancreatic fistula, including Grade BL, Grade B and Grade C
Time frame: in 30 days following gastrectomy
The mortality of Grade B and C Pancreatic Fistula
the percentage of patients died of Grade B or C pancreatic fistula
Time frame: in 30 days following gastrectomy
Started Dec 2017 (actual). Primary completion is estimated for Nov 2018, 11 months after the start.
Of 323 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 11 months is below that.
Counting every sponsor, half of 365 studies reached it within 54 months; a quarter within 29 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.